** Shares of vaccine maker Moderna MRNA.O and gene therapy developers fall between 12% and 22% after the U.S. FDA named Vinay Prasad as the director of its Center for Biologics Evaluation and Research (CBER)
** Prasad was a fierce critic of COVID-19 vaccine and mask mandates
** As the director of CBER, Prasad will oversee the regulation of vaccines and gene therapies
** Shares of Moderna down 12.4%, Novavax NVAX.O down 5.2%, while Pfizer PFE.N, previously down after an announcement on medicine costs, extends losses to 3%
** Shares of gene therapy developers such as Sarepta Therapeutics SRPT.O fall 21.5%, Taysha Gene Therapies TSHA.O fall 20.7%, Capricor Therapeutics CAPR.O down 20.3%
** U.S.-listed shares of CRISPR Therapeutics CRSP.BN down 9.6%, Solid Biosciences SLDB.O down 15.3%,
** MRNA down 41.3% and SRPT down 61.1% YTD
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.